# AtaiBeckley Inc. (ATAI) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_172ba7401e33c143fe3c · retrieved 2026-08-12T07:23:45.359Z

## Overview
AtaiBeckley Inc. is a clinical-stage biotechnology company developing rapid-acting, durable and convenient mental health treatments, with a pipeline including BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (granted Breakthrough Therapy Designation and in Phase 3), VLS-01 (DMT buccal film) for treatment-resistant depression in Phase 2, and EMP-01 ((R)-MDMA HCI) for s…

On July 15, 2026, AtaiBeckley Inc. agreed to be acquired by Eli Lilly and Company (Lilly) pursuant to an Agreement and Plan of Merger. Under the merger agreement, each outstanding share of AtaiBeckley common stock will be converted into the right to receive $6.75 in cash at closing, without interest and less applicable tax withholdings, plus one contingent value right (CVR) representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement of specified clinical and regulatory milestones. The upfront cash consideration of $6.75 per share represents a premium of approximately 40% to the 30-day volume-weighted average trading price of AtaiBeckley common stock ended on July 15, 2026. The merger is expected to close in the third quarter of 2026, subject to customary closing conditions including stockholder approval and regulatory clearances under the Hart-Scott-Rodino Act and antitrust laws of Australia, Germany, the United Kingdom, and a specified "Springing Jurisdiction."

## Terms
- Counterparty: Eli Lilly and Company · Deal value: $2.80B · Consideration: mixed · Premium: 40.0% · Price/share: $6.75

## Key dates
- Announced 2026-08-10 · Record 2026-08-07 · Vote 2026-09-08 · Expected close 2026-09-30

## Timeline
- 2026-08-10 · DEFM14A (0001140361-26-031922): DEFM14A - AtaiBeckley Inc. — *AtaiBeckley Inc. is a clinical-stage biotechnology company developing rapid-acting, durable and convenient mental health treatments, with a pipeline including BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (granted Breakthrough Therapy Designation and in Phase 3), VLS-01 (DMT buccal film) for treatment-resistant depression in Phase 2, and EMP-01 ((R)-MDMA HCI) for s…* On July 15, 2026, AtaiBeckley Inc. agreed to be acquired by Eli Lilly and Company (Lilly) pursuant to an Agreement and Plan of Merger. Under the merger agreement, each outstanding share of AtaiBeckley common stock will be converted into the right to receive $6.75 in cash at closing, without interest and less applicable tax withholdings, plus one contingent value right (CVR) representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement of specified clinical and regulatory milestones. The upfront cash consideration of $6.75 per share represents a premium of approximately 40% to the 30-day volume-weighted average trading price of AtaiBeckley common stock ended on July 15, 2026. The merger is expected to close in the third quarter of 2026, subject to customary closing conditions including stockholder approval and regulatory clearances under the Hart-Scott-Rodino Act and antitrust laws of Australia, Germany, the United Kingdom, and a specified "Springing Jurisdiction."
  https://www.sec.gov/Archives/edgar/data/2081043/0001140361-26-031922.txt

## Citations
- 0001140361-26-031922 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126031922